Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P43320

UPID:
CRBB2_HUMAN

ALTERNATIVE NAMES:
Beta-B2 crystallin; Beta-crystallin Bp

ALTERNATIVE UPACC:
P43320; Q9UCM8

BACKGROUND:
The Beta-crystallin B2 protein, alternatively named Beta-crystallin Bp, is a dominant structural element in the vertebrate eye lens. It ensures the lens's clarity and focusing ability, which are vital for vision. As a member of the crystallins family, it significantly contributes to the lens's optical properties.

THERAPEUTIC SIGNIFICANCE:
Linked to Cataract 3, multiple types, Beta-crystallin B2's gene variants are associated with the development of cataracts, marked by lens clouding and potential blindness. Exploring Beta-crystallin B2's function offers a promising avenue for discovering new cataract treatments, potentially improving vision restoration techniques.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.